A Prospective Study of Orelabrutinib plus Obinutuzumab (O2) in Treatment-naïve Marginal Zone Lymphoma (MZL): Preliminary Analysis on Efficacy and Safety (Abstract No.: 815MO)

Orelabrutinib-based Regimens in Chronic Lymphocytic Leukemia with Comorbidities: A Real-World Study (Abstract No.: 840P)

Efficacy and Safety of Orelabrutinib plus R-CHOP-like Regimens for Treatment-naïve Diffuse Large B-cell Lymphoma with Double Expression (Abstract No.: 819P)

Fixed-duration Orelabrutinib plus Bendamustine and Rituximab versus Continuous Bruton Tyrosine Kinase Inhibitor (BTKi) in Treatment-naïve Chronic/small Lymphocytic Leukemia (CLL/SLL): A Multicenter, Nonrandomized, Pragmatic Clinical trial (Abstract No.: 846TiP)

Orelabrutinib combined with Rituximab for the Treatment of Elderly patients with newly diagnosed non-GCB diffuse large B-cell lymphoma (DLBCL) under the guidance of genetic subtype: A prospective, multicenter, single-arm, response-adaptive clinical study (Origin) (Abstract No.: 844TiP)

Subcutaneous ICP-B02 (CM355) , a Novel Bispecific CD20/CD3 Antibody Showed Promising Efficacy and Favorable Safety Profile in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Dose-Escalation Data from a Phase I/II Trial

A Phase II, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Tafasitamab Combined with Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Preliminary Safety and Efficacy Data from Patients with Relapsed or Refractory B-Cell Malignancies Treated with ICP-248, a Novel BCL2 Inhibitor

Orelabrutinib, Rituximab and High-Dose Methotrexate (HD-MTX) in Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL): A Retrospective Analysis on Efficacy and Safety

Different Subtype of DLBCL Patients Treated with R-Chop (Like) Plus Orelabrutinib Regimen: A Real-World Study

Phase II Study of Orelabrutinib, Rituximab and Thiotepa (ORT) Combined with or without High-Dose MTX Therapy in Patients with Primary CNS Lymphoma

Real-World Analysis of Orelabrutinib in Patients (PTS) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (CWCLL-001 Study)

Orelabrutinib in Patients with Indolent Non-Hodgkin Lymphoma (INHL) Intolerant to Prior Bruton Tyrosine Kinase Inhibitors (BTKI): Preliminary Results from a Phase 2 Study

Real-World Outcomes of Orelabrutinib as First-Line Treatment in CLL/SLL: A Multicenter Study

Orelabrutinib in Combination with PD-1 Inhibitor Inrefractory or Relapsed Primary CNS Lymphoma

The Primary Results of R-MTO Regimen (Rituximab, Methotrexate, Thiotepa, and Orelabrutinib) as the First-Line Induction Therapy in Newly Diagnosed Primary Central Nervous System Lymphoma

Orient Study: Orelabrutinib Addition to R-Chop-Like Regimen Adapted to Response in Treatment-Naïve Non-GCB DLBCL

Orelabrutinib-Lenalidomide-Rituximab in Patients with Untreated Mantle Cell Lymphoma (MCL): Updated Results of Themulticenter, Phase II Polaris Study

Efficacy and Safety of a Highly Selective Oral TYK2/JAK1 Inhibitor, ICP-332, in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase II, Randomized, Placebo-Controlled Trial

A Prospective Multicenter Phase II Study of Orelabrutinib-Lenalidomide-Rituximab (OLR) in Patients with Untreated Mantle Cell Lymphoma (MCL) in China (POLARIS Study): Preliminary Analysis on Efficacy, Safety, Mutation Spectrum and Impact of Mutation Profiling on Treatment Responses

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)

Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Waldenström's Macroglobulinemia in a Single-Arm, Multicenter, Open-Label, Phase 2 Study: Long Term Follow-up Results

Preliminary safety, pharmacological and efficacy data from patients with relapsed or refractory B-cell malignancies treated with the ICP-248, a next generation BCL2 inhibitor

Effectiveness and Safety of Orelabrutinib Combined with Rituximab As First-Line Treatment in Marginal Zone Lymphoma

Orelabrutinib plus R-CHOP regimen in treatment-naïve patients with TP53-mutated diffuse large B-cell lymphoma (DLBCL)

Efficacy and safety of orelabrutinib- containing TORM regime as first-line therapy in primary central nervous system lymphoma (PCNSL): a retrospective analysis

Preliminary Results of Phase 1 Trial of Orelabrutinib in Combination with Rituximab, Methotrexate, and Dexamethasone in Patients with Newly Diagnosed Primary CNS Lymphoma Implementing Bayesian Design for Dose-Seeking

Effectivness and Safety of Orelabrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Retrospective, Real-World Study in China

Pomalidomide, Rituximab, Orelabrutinib, and Minichop-like (PRO-miniCHOP) in Elderly Patients with Newly Diagnosed Diffuse Large-B Cell Lymphoma: Preliminary Results from a Phase II Study

Orelabrutinib, an Irreversible Inhibitor of Bruton's Tyrosine Kinase, for Treatment of Primary Immune Thrombocytopenia: Results of a Randomized, Open-Label Phase II Study

Orient Study: Regimen of Orelabrutinib plus R-CHOP-Like for Patients with Newly Diagnosed Untreated Non-GCB DLBCL

Preliminary Findings of a Phase II Study of Chemo-Free Combination of Pomalidomide, Orelabrutinib, Rituximab with Sequential High-Dose Methotrexate in Newly Diagnosed Primary CNS Lymphoma

Orelabrutinib, a New-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma

Orelabrutinib-Lenalidomide-Rituximab (OLR) in Patients with Untreated Mantle Cell Lymphoma (MCL): A Prospective, Multicenter, Single-Arm Phase 2 Polaris Study in China

Combination of BTK Inhibitor Orelabrutinib, Anti-CD19 Antibody Tafasitamab, and IMiD Lenalidomide for the Treatment of B Cell Malignancies (Abstract Number: 4013)

Preclinical Development of SHP2 Allosteric Inhibitor ICP-189 (Abstract Number: 4012)

ICP-490 Is a Highly Potent and Selective IKZF1/3 Degrader with Robust Anti-Tumor Activities against Multiple Myeloma and Non-Hodgkin’s Lymphoma (Abstract Number: 3427)

Gunagratinib, a Highly Selective Irreversible FGFR Inhibitor, in Patients with Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma Harboring FGFR Pathway Alterations: A Phase IIa Dose-Expansion Study

Orelabrutinib, Rituximab, and High-Dose Methotrexate (HD-MTX) in Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL): A Retrospective Analysis on Efficacy, Safety, and Biomarker

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of Orelabrutinib Plus R-CHOP Versus Placebo Plus R-CHOP in Treatment-Naïve Patients with Mcd Subtype Diffuse Large B-Cell Lymphoma

Orelabrutinib plus RCHOP for Previously Untreated Non-Germinal Center B Cell-like (GCB) Diffuse Large B Cell Lymphoma (DLBCL) Patients with Extranodal Disease

Preliminary Results of a Phase II Study of Orelabrutinib in Combination with Anti-PD-1 Monoclonal Antibody in Refractory or Relapsed Primary CNS Lymphoma

ICP-723 Is a Potent Pan-TRK Inhibitor with Robust Anti-Tumor Activities against Wild-Type and Acquired Drug-Resistant Mutations of NTRK Fusions

Phase I Results of Gunagratinib (ICP-192), a Highly Selective Irreversible FGFR 1-4 Inhibitor in Patients with Head and Neck Cancer Harboring FGF/FGFR Gene Aberrations

Safety, Pharmacokinetics (PK), and Clinical Efficacy of ICP-723, a Highly Selective Next-Generation Pan-TRK Inhibitor, in Patients with Solid Tumor

Efficacy and Safety of Orelabrutinib in Diffuse Large B-cell Lymphoma: A Real-World Analysis

Orelabrutinib, An Irreversible Inhibitor of Bruton's Tyrosine Kinase (BTK), for the Treatment of Systemic Lupus Erythematosus (SLE): Results of A Randomized, Double-Blind, Placebo-Controlled, Phase IB/IIA Dosefinding Study (Abstract Number: LB0005)

Efficacy and Safety of Orelabrutinib in Relapsed/Refractory Waldenstrom's Macroglobulinemia Patients

Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Updated Long Term Results of Phase II Study

Orelabrutinib, a Selective Bruton's Tyrosine Kinase (BTK) Inhibitor in the Treatment of Primary Immune Thrombocytopenia (ITP)

Phase I Result of ICP-192 (Gunagratinib), a Highly Selective Irreversible FGFR Inhibitor, in Patients with Advanced Solid Tumors Harboring FGFR Pathway Alterations

Long-Term Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study

Updated Results from the Phase II Study of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia

Pooled Analysis of Safety Data from Clinical Trials of Orelabrutinib Monotherapy in Hematologic Malignancies

Orelabrutinib, a Potent and Selective Bruton's Tyrosine Kinase Inhibitor with Superior Safety Profile and Excellent PK/PD Properties

Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study

Safety, Tolerability and Efficacy of Orelabrutinib, Once a Day, to Treat Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia